BAARERSTRASSE 14, ZUG, V8
CRISPR Therapeutics Files Prospectus Supplement for $600 Million Offering
Provides Business Update and Reports Second Quarter 2025 Financial Results
Other Events
Amendments to Articles of Incorporation or Bylaws, Shareholder votes
News, Legal Opinion, Material Contracts
Earnings Release
Annual Report to Security Holders
Announces Transition of Chief Operating Officer
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence